Format

Send to

Choose Destination
Nat Med. 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

Author information

1
Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA.
2
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
3
Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
4
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
5
Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
6
Cancer and Developmental Therapeutics Program, Buck Institute for Research on Aging, Novato, California, USA.
7
Department of Anatomy, University of California, San Francisco, San Francisco, California, USA.
8
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
9
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
10
Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

Abstract

Triple-negative breast cancer (TNBC), in which cells lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and the ERBB2 (also known as HER2) receptor, is the breast cancer subtype with the poorest outcome. No targeted therapy is available against this subtype of cancer owing to a lack of validated molecular targets. We previously reported that signaling involving MYC-an essential, pleiotropic transcription factor that regulates the expression of hundreds of genes-is disproportionally higher in triple-negative (TN) tumors than in receptor-positive (RP) tumors. Direct inhibition of the oncogenic transcriptional activity of MYC has been challenging to achieve. Here, by conducting a shRNA screen targeting the kinome, we identified PIM1, a non-essential serine-threonine kinase, in a synthetic lethal interaction with MYC. PIM1 expression was higher in TN tumors than in RP tumors and was associated with poor prognosis in patients with hormone- and HER2-negative tumors. Small-molecule PIM kinase inhibitors halted the growth of human TN tumors with elevated MYC expression in patient-derived tumor xenograft (PDX) and MYC-driven transgenic mouse models of breast cancer by inhibiting the oncogenic transcriptional activity of MYC and restoring the function of the endogenous cell cycle inhibitor, p27. Our findings warrant clinical evaluation of PIM kinase inhibitors in patients with TN tumors that have elevated MYC expression.

PMID:
27775705
PMCID:
PMC5341692
DOI:
10.1038/nm.4213
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center